作者: Chien-Hsing Chang , Edmund A. Rossi , David M. Goldenberg
DOI:
关键词:
摘要: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, antibody is veltuzumab epratuzumab. Administration subject induces apoptosis cell death target cells in diseases such as B-cell lymphomas leukemias, autoimmune disease immune dysfunction disease. In most preferred embodiments, increase levels phosphorylated p38 PTEN, decrease Lyn, Akt, ERK, IKKα/β IκBα, expression RKIP Bax Mcl-1, Bcl-xL, Bcl-2, phospho-BAD cells. The show EC50 values for inhibiting tumor growth low nanomolar even sub-nanomolar concentration range.